Beyond the branded products currently sold by Mallinckrodt and Endo, the companies say the combined business will also have a strong foundation in rare and orphan diseases. Generic medicines will be spun out as a separate company.
The post Pharma Firms Mallinckrodt and Endo Agree to Merge in $6.7B Cash and Stock Deal appeared first on MedCity News.
